| Contributors: |
Gastaldi, Matteo; Foiadelli, Thoma; Greco, Giacomo; Scaranzin, Silvia; Rigoni, Eleonora; Masciocchi, Stefano; Ferrari, Sergio; Mancinelli, Chiara; Brambilla, Laura; Mancardi, Margherita; Giacomini, Thea; Ferraro, Diana; Della Corte, Marida; Gallo, Antonio; Di Filippo, Massimiliano; Benedetti, Luana; Novi, Giovanni; Versino, Maurizio; Banfi, Paola; Iorio, Raffaele; Moiola, Lucia; Turco, Emanuela; Sartori, Stefano; Nosadini, Margherita; Ruggieri, Martino; Savasta, Salvatore; Colombo, Elena; Ballante, Elena; Jarius, Sven; Mariotto, Sara; Franciotta, Diego; Nina Study Group: Rossi, Francesca; Luigi, Zulliani; Mampreso, Edoardo; Gambara, Silvia; Siquilini, Sabrina; Matricardi, Sara; Torri Clerici, Valentina; Polito, Anna Nunzia; Di Rosa, Gabriella; Bedin, Roberta; Vitetta, Francesca; Varone, Antonio; Maimone, Davide; Bisecco, Alvino; Di Sabatino, Elena; Scannapieco, Sara; Papi, Claudia; Guerrieri, Simone; Pisani, Francesco; Praticò, Andrea; Po, Chiara; Grazian, Luisa; Passarini, Alice; Bergamoni, Stefania; Rasia, Sasha; Bergamaschi, Roberto; Marchioni, Enrico |
| Description: |
Background: IgG antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) define a subset of associated disorders (myelin oligodendrocyte glycoprotein associated disorders (MOGAD)) that can have a relapsing course. However, information on relapse predictors is scarce. The utility of retesting MOG-IgG over time and measuring their titres is uncertain. We aimed to evaluate the clinical relevance of longitudinal MOG-IgG titre measurement to predict relapses in patients with MOGAD. Methods: In this retrospective multicentre Italian cohort study, we recruited patients with MOGAD and available longitudinal samples (at least one >3 months after disease onset) and tested them with a live cell-based assay with endpoint titration (1:160 cut-off). Samples were classified as 'attack' (within 30 days since a disease attack (n=59, 17%)) and 'remission' (≥31 days after attack (n=295, 83%)). Results: We included 102 patients with MOGAD (57% adult and 43% paediatric) with a total of 354 samples (83% from remission and 17% from attack). Median titres were higher during attacks (1:1280 vs 1:640, p=0.001). Median onset titres did not correlate with attack-related disability, age or relapses. Remission titres were higher in relapsing patients (p=0.02). When considering the first remission sample available for each patient, titres >1:2560 were predictors of relapsing course in survival (log rank, p |